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Abstract
Background: Methylphenidate (MPH), the first choice medication for attention-deficit hyperactivity disorder (ADHD), is
associated with serious adverse effects like arrhythmia. Evidence on the association of ADHD with immune and
oxidant-antioxidant imbalances offers potential for antioxidant and/or immunomodulatory nutritional supplements as
ADHD therapy. One small randomised trial in ADHD suggests, despite various limitations, therapeutic benefit from
Pycnogenol®, a herbal, polyphenol-rich extract.
Methods: This phase III trial is a 10-week, randomised, double-blind, placebo and active treatment controlled multicentre
trial with three parallel treatment arms to compare the effect of Pycnogenol® to MPH and placebo on the behaviour of
144 paediatric ADHD and attention-deficit disorder (ADD) patients. Evaluations of behaviour (measured by the ADHD-
Rating Scale (primary endpoint) and the Social-emotional Questionnaire (SEQ)), immunity (plasma cytokine and antibody
levels, white blood cell counts and faecal microbial composition), oxidative stress (erythrocyte glutathione, plasma
lipid-soluble vitamins and malondialdehyde and urinary 8-OHdG levels, as well as antioxidant enzyme activity and gene
expression), serum zinc and neuropeptide Y level, urinary catecholamines and physical complaints (Physical Complaints
Questionnaire) will be performed in week 10 and compared to baseline. Acceptability evaluations will be based on
adherence, dropouts and reports of adverse events. Dietary habits will be taken into account.
Discussion: This trial takes into account comorbid behavioural and physical symptoms, as well as a broad
range of innovative immune and oxidative biomarkers, expected to provide fundamental knowledge on
ADHD aetiology and therapy. Research on microbiota in ADHD is novel. Moreover, the active control arm is
rather unseen in research on nutritional supplements, but of great importance, as patients and parents are
often concerned with the side effects of MPH.
Trial registration: Clinicaltrials.gov number: NCT02700685. Registered on 18 January 2016. EudraCT
2016-000215-32. Registered on 4 October 2016.
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Background
Attention-deficit hyperactivity disorder (ADHD) is a com-
mon neurocognitive behavioural disorder with childhood
onset and core symptoms of hyperactivity, impulsivity and
inattention [1]. ADHD has a worldwide prevalence of 5.9–
7.1% and is associated with other psychiatric disorders,
such as oppositional defiant disorder (ODD), autism and
anxiety [2, 3].
Methylphenidate (MPH), the first-choice medication for
ADHD, is a central nervous system stimulant. It increases
attentiveness and reduces hyperactivity and impulsivity by
inhibition of dopamine reuptake in the striatum, without
triggering its release. MPH is prescribed for chronic use to
a large proportion of ADHD patients, but is linked to pos-
sible publication bias in reported efficacy [4–6]. In
addition, parents are often disinclined to use MPH due to
its negative publicity and its frequent side effects, includ-
ing serious side effects like arrhythmia, and, subsequently,
nonadherence to therapy is high [4–7]. A recent review
reports adverse effects, like insomnia and decreased appe-
tite, in about 25% of patients using MPH [8]. Other thera-
peutic options are therefore warranted, at least for a
subgroup of patients [4, 5, 7, 8].
ADHD is a complex and multifactorial disorder, influ-
enced by both genetics and the environment. Its exact
pathophysiology remains, however, unclear. Dopamin-
ergic dysfunction is involved, but also associations with
immune and oxidant-antioxidant imbalances exist [9,
10]. Various studies demonstrated, for example, increased
levels of plasma malondialdehyde (MDA) and exhalant eth-
ane (oxidative stress markers) and decreased activity of
antioxidant enzymes such as glutathione peroxidase (GPX)
and catalase (CAT) [11–14]. ADHD has also been hypothe-
sised to be a hypersensitivity disorder, with a disrupted im-
mune regulation contributing to its aetiology [10]; i.e.
ADHD has comorbidity with both Th1- and Th2-mediated
disorders and several related genes have immune functions
[9, 10, 15–18]. Ceylan et al. observed increased levels of ad-
enosine deaminase, a marker of cellular immunity, and of
the oxidative enzymes xanthine oxidase (XO) and nitric
oxide synthase, and decreased levels of the antioxidant en-
zymes glutathione-S-transferase and paraoxonase-1. These
results indicate the involvement of oxidative changes and
cellular immunity in ADHD [9].
Still, specific immune biomarkers other than antibodies
have not been systematically studied in ADHD despite
growing evidence on associations in autism [19, 20]. In
addition, immune and oxidative effects of both standard
therapy and nutritional supplementation in ADHD are
neglected topics in research. Yet, immune and oxidative
imbalances linked with ADHD offer potential for appro-
priate supplementation in ADHD therapy [21].
Due to its antioxidant and immunomodulatory proper-
ties, a commercially available standardised extract from
French maritime pine (Pinus pinaster) bark with a high
content of polyphenolic compounds (including phenolic
acids and procyanidins), Pycnogenol®, was selected for this
study [22–24]. One small randomised trial and few obser-
vational studies suggest its therapeutic benefit in ADHD.
Still, this trial had some limitations (e.g. short supplemen-
tation period) and the mechanisms of action involved
remain unclear [22, 25–29]. The efficacy, mechanism(s) of
action and value of Pycnogenol® in ADHD as compared to
MPH treatment thus remain to be confirmed.
Methods
Objective
To evaluate the effect of Pycnogenol® on ADHD and
ADD behaviour and comorbid physical and psychiatric
symptoms, as well as on immunity, oxidative damage,
antioxidant status and neurochemical parameters, as
compared to placebo and MPH treatment.
Hypotheses
1. In ADHD therapy, Pycnogenol® is more effective
than placebo and not less effective than MPH
2. As compared to placebo and MPH, Pycnogenol®
increases antioxidant levels, reduces oxidative
damage, improves immune and neurochemical
status and reduces comorbid physical and
psychiatric complaints
3. The tolerability of Pycnogenol® is higher than that of
MPH
Design
This is a phase III, randomised, double-blind, placebo
and active product controlled, multicentre clinical trial
with three parallel treatment arms to compare effects on
ADHD and ADD behaviour between Pycnogenol®, MPH
(Medikinet® Retard) and placebo, using the ADHD-
Rating Scale (ADHD-RS) as a primary outcome meas-
ure. Secondary outcome measures are comorbid physical
and psychiatric complaints (including side effects), oxi-
dative stress, immunity, neurochemical parameters and
tolerance of the intervention. Following screening and
baseline assessments, 144 patients (aged 6–12 years) will
receive one of the three treatments for 10 weeks (see
Table 2). Evaluations will be performed in weeks 5 and
10, as compared to baseline. Dietary habits will be taken
into account.
Two visits with similar evaluations and sample collections
will be conducted: at baseline and after 10 weeks. To ana-
lyse biomarkers of interest, 16 ml of venous blood will be
collected at the start and the end of intervention, as well as
urine. Faecal samples will be collected from participant sub-
groups (n = 60). Next to baseline and final evaluations, an
extra evaluation of behaviour and physical symptoms will
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be conducted in week 5 by means of questionnaires. Two
reminders will be sent in case questionnaires are not re-
ceived within 1 week after the required date. After every
blood and urine collection and when questionnaires are
completed, participants will receive two movie tickets.
Inclusion and randomisation
Recruitment starts in March 2017. The trial population
will consist of ADHD and ADD patients recruited at the
University Hospitals of Antwerp (UZA) and Ghent (UZ
Ghent) and the Hospital Network Antwerp (ZNA). With
an expected inclusion rate of 30–50 patients per year
(10–20 participants in UZA, 15–20 in UZ Ghent and 5–
10 in ZNA), about 3 years will be required for subject
recruitment. Though, as compared to inclusion rate, a
ten-fold higher diagnosis rate of ADHD and ADD is ex-
pected in these centres, inclusion and exclusion criteria
of the proposed trial (e.g. regarding autism or the recent
intake of supplements or medication) are expected to
exclude at least half of all newly diagnosed patients,
while a consent rate of 30% is expected, taking into ac-
count potential reluctance regarding the use of medica-
tion or supplements, as well as ‘risk’ for placebo
treatment [30, 31]. In addition, patients from random
primary schools in Flanders will be invited for this trial
by letters and diagnosed in one of the trial centres be-
fore inclusion. In case of slow recruitment, also ‘ZitStil’
(information centre on ADHD/ADD), revalidation cen-
tres, independent child psychiatrists/paediatricians and
other hospitals may be involved. Patients meeting eligi-
bility criteria (Table 1) will be informed in detail and
written consent of the legal representative to participate
in the trial will be obtained prior to inclusion.
Participants will be randomised, stratified by trial centre,
to one of the three treatment arms (placebo, Pycnogenol®,
or Medikinet® Retard) by randomization.com randomisa-
tion software (original generator, different starting number
across trial sites, and taking into account body weights
below and above 30 kg; Fig. 1). The number of patients per
trial site is not limited. The involved physicians and hospital
pharmacies will assure confidentiality by retaining the ran-
domisation code at all times in a sealed envelope, only to
be used in case of emergency or serious adverse events.
Treatment
Patients will receive all capsules required for the
complete study at inclusion, at a dose based on their
body weight (one or two orally administered capsules at
breakfast):
 MPH (Medikinet® Retard, methylphenidate
hydrochloride modified release): patients with a
body weight below 30 kg will receive 20 mg/day,
those with a body weight of 30 kg or over, 30 mg/
day. Treatment during the first week always
contains 10 mg, increasing by 10 mg per week to
limit side effects
 Pycnogenol®: patients with a body weight below
30 kg will receive 20 mg/day, those with a body
weight of 30 kg or over, 40 mg/day, aiming at a daily
dose of 1 mg/kg and taking into account
formulation issues [22]. Treatment during the first
2 weeks always contains 20 mg
 Placebo: contains excipients only
In case of adverse events, the investigator, principal
caregiver and participant can decide to discontinue the
trial medication/supplement. However, no dose adjust-
ment will be performed. Using a standardised question-
naire, adverse events will be documented at weeks 5 and
10, also taking into account the patient’s medical records.
Additionally, spontaneously reported adverse events will
be recorded. In case of a serious adverse event, the trial
code will be broken and treatment discontinued. In case
10% of participants experience a potentially related serious
adverse event, the trial will be discontinued.
Table 1 Inclusion and exclusion criteria for patient selection
Inclusion criteria Exclusion criteria
1. Age 6–12 years (both inclusive) 1. Diagnosis of autism spectrum disorder
2. ADHD diagnosis a. based upon the diagnostic interview by
the investigating physician b. based upon the ADHD-RS
2. Pervasive developmental disorder, personality disorder, IQ <70, conduct
disorder (CD), tics, schizophrenia, dyskinesia, personal or family history of
psychotic disorder, bipolar illness, depression, or suicide attempt
3. Responsible caregiver to provide information about the
patient’s functional status
3. Chronic medical disorder or acute inflammatory disease. Glaucoma, heart
disease, high blood pressure, or peripheral vascular disease
4. Patient and responsible caregiver have a sufficient level of
knowledge of Dutch
4. Use of MAO inhibitor 14 days before inclusion. Use of clonidine, guanethidine,
seizure medicine, antidepressants, blood thinners, blood pressure, or diet
medication 3 months before inclusion
5. Written informed consent by the patient’s legally accepted
representative
5. Use of vitamin/mineral/herbal/omega-3 supplements or any medication for
longer than 1 week, 3 months before inclusion
6. Other contraindications for MPH or Pycnogenol®, as defined in the Summary of
Product Characteristics and Investigator’s Brochure, respectively
ADHD attention-deficit hyperactivity disorder, ADHD-RS, ADHD-Rating Scale, MAO monoamine oxidase, MPH methylphenidate
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Pycnogenol® and placebo will be produced in capsules
identical to Medikinet® Retard (Medice GmbH). All
treatments will be provided in identical jars, labelled
with the subject’s trial number and week of intake. Com-
pliance will be determined based on accountability of
investigational products and self-reported adherence.
Primary outcome
As the primary objective is to assess the efficacy of
Pycnogenol® for improving ADHD and ADD behav-
iour as rated by teachers compared to placebo and
Medikinet® Retard, the primary outcome is the
summed ADHD score of the ADHD-RS as rated by
teachers (Table 2). Teachers will fill out this question-
naire before the start of the intervention and after 5
and 10 weeks.
Secondary outcomes
ADHD/ADD behaviour Secondary outcomes related to
ADHD/ADD behaviour are:
 Summed ADHD score of the ADHD-RS, rated by
parents
 Summed ADHD score of the Social-emotional
Questionnaire (SEQ), rated by parents and teachers
 Scores on ADHD subscales of the ADHD-RS and
SEQ, rated by parents and teachers (hyperactivity,
impulsivity and inattention)
 Percentage of responders rated by parents and
teachers, defined as participants with a reduction of
at least 20% of their baseline summed ADHD-RS
score [32]
Other objectives are to evaluate the effect of Pycno-
genol® compared to placebo and MPH on comorbid psy-
chiatric and physical complaints, antioxidant levels,
oxidative damage, immunity and neurotransmitters.
Other secondary outcomes are, therefore:
Psychiatric complaints
 Social behaviour problems subscale of the SEQ,
rated by parents and teachers, to evaluate to
what extent symptoms of ODD and CD are
displayed [33]
 Anxiety subscale of the SEQ, rated by parents
and teachers, to evaluate symptoms of general
anxiety, social anxiety and anxiety-depression [33]
Physical complaints
 Physical and sleep complaints, including various
potential side effects, measured by the Physical
Complaints Questionnaire (PCQ) [34]
Antioxidant levels
 Erythrocyte glutathione (GSH) level, the most
important intracellular antioxidant, analysed by
HPLC with electrochemical detection [35]
Fig. 1 Design of the trial
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 Lipid-soluble antioxidants: plasma vitamin E (α- and
γ-tocopherol), vitamin A (β-carotene, retinol, retinyl
palmitate) and co-enzyme Q10, analysed by HPLC
with coulometric detection [36–39]
 Antioxidant enzyme activity (CAT, SOD and
GPX) and total antioxidant status, analysed by
Enzyme-linked ImmunoSorbent Assay (ELISA)
[11, 40]
 Gene expression, quantified by RT-qPCR, focus-
ing on networks counteracting oxidative stress
(GPX, CAT, superoxide dismutase (SOD), XO)
and stress-related proteins (clusterin, apolipopro-
tein J) [41, 42]
 Serum zinc level, analysed by atomic absorption
spectroscopy (AAS) [43]
Oxidative damage
 Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG)
level, marker of oxidative deoxyribonucleic acid
(DNA) damage, corrected for urinary creatinine
concentration, analysed by ELISA [44]
 Plasma malondialdehyde (MDA) level, marker of
lipid peroxidation, analysed by HPLC with
fluorescence detection [45]
Immunity
 Plasma cytokines for monocytes (interleukin (IL)-1β,
IL-6, IL-8, IL-10, IL-12, tumour necrosis factor
(TNF)-α) and T-cells (IL-4, IL-5, IL-6, IL-10, inter-
feron (IFN)-γ) as well as antibody levels (IgA1–2,
IgG1–4, IgE) by flow cytometry and ELISA, as markers
of immune activation state and skewing [21, 46, 47]
 Identification of peripheral blood mononuclear cells
(PBMCs) like neutrophils, CD4, CD8 and B-cells
and measurement of their functional responses (e.g.
cytokine release) after stimulation, as a marker of
immune activation state, skewing and responsivity
[21, 46, 47]
 Intestinal microbial composition, assessed using
extreme throughput multiplexed sequencing of 16S
ribosomal ribonucleic acid (RNA) gene pools
polymerase chain reaction (PCR)-amplified from
intestinal content samples [48, 49]
Neurochemistry
 Urinary catecholamines (dopamine, noradrenaline
and adrenaline) and their metabolites, determined
by HPLC with coulometric detection [50]
 Serum neuropeptide Y (NPY), analysed by ELISA [51]
The final objective is to investigate the acceptability of
Pycnogenol® compared to Medikinet® Retard and placebo,
based on the prevalence of side effects, treatment adher-
ence (defined as more than 90% ingestion as scheduled)
and proportion of dropouts.
Dietary habits of participants, such as consumption of
vegetables, chocolate, fruit, etc., will be assessed by a
Food Frequency Questionnaire (FFQ) at the start and
end of intervention [52, 53], to assess potential dietary
adaptations during the study as well as baseline differ-
ences between treatment groups. The highest educa-
tional achievement of both parents will be determined
as a proxy for socioeconomic status.
Table 2 Investigations and data acquisition during the trial
Screening Baseline




Inclusion and exclusion criteria X X
Current use of medication/
supplements





Medication count X X
ADHD-RS X X X
SEQ X X
PCQ X X X
FFQ X X
Blood and urine collection X X
Faeces collection X X
GSH analysis X X
Lipid-soluble antioxidants analysis X X
Antioxidant enzyme activity X X
Genetics analysis X X
MDA analysis X X
8-OHdG analysis X X
Cytokine analysis X X
Antibody analysis X X
PBMC count and reactivity
analysis
X X
Microbial composition analysis X X
Catecholamine analysis X X
NPY analysis X X
Zinc analysis X X
8-OHdG 8-hydroxy-2-deoxyguanosine, ADHD-RS ADHD-Rating Scale, FFQ
Food Frequency Questionnaire, GSH erythrocyte glutathione, MDA
plasma malondialdehyde, NPY serum neuropeptide Y, PBMC peripheral
blood mononuclear cell, PCQ Physical Complaints Questionnaire, SEQ
Social-Emotional Questionnaire
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Statistics
For the estimation of the required sample size, the fol-
lowing assumptions were made:
 Patients improve by 0.75 standard deviation (SD) on
the ADHD-RS summed ADHD score as rated by
teachers if using Pycnogenol® for 10 weeks [22, 54],
which corresponds to a 20% improvement with ac-
tive treatment as compared to placebo
 Power of 80%, dropout of 20%
 Two-sided testing, at a significance level of 0.05 with
Bonferroni post-hoc testing correction
Based on these considerations, 48 patients per group
will be necessary (n = 144 in total).
Data will be checked for outliers. Missing data will not
be accounted for. The three groups will be compared
with regard to baseline characteristics. A two-way ana-
lysis of variance (ANOVA) will be performed to investi-
gate a potential interaction between treatment and
weight. Change in ADHD-RS score as rated by teachers
(primary outcome measure) will be compared between
the three groups by means of a one-way ANOVA (cat-
egories: group, time; α = 0.05) with post-hoc testing.
Changes regarding secondary target variables will also be
compared between the three groups, by one-way
ANOVA with post-hoc analysis with multiple testing
correction, Kruskal-Wallis, or Fisher’s exact test. Separ-
ate analyses for subgroups (e.g. based on gender, severity
of ADHD, dietary habits, etc.) will be performed. Nonin-
feriority of Pycnogenol® as compared to Medikinet® Re-
tard will be demonstrated when the difference in effect
on ADHD-RS score is no more than 5 points [55]. This
wide margin might be justified due to frequent side ef-
fects of MPH. Noninferiority will only be accepted if
supported by both intention-to-treat and per-protocol
analyses [56, 57].
Ethics and registration
Ethical approval has been obtained in UZA (EC 15/35/
365), ZNA (EC approval 4656) and UZ Ghent (2016/
0969). The trial has been registered at ClinicalTrials.gov
(NCT02700685) and EudraCT (2016-000215-32).
Trial management and research team
The University of Antwerp (Laboratory of Nutrition and
Functional Food Science) is the sponsor of this trial,
with NH being the coordinating investigator. As
principle investigators, BC, DVW and HV will be pri-
marily responsible for patient inclusion. NH and AV are
responsible for the analysis of oxidative stress and
neurological biomarkers and questionnaire results, as
well as data management. HS is responsible for the ana-
lysis of immune biomarkers and genetics. No Data
Monitoring Committee will be set up. BC, HV, DVW,
NH and AV will discuss potential issues regarding, e.g.
subject recruitment.
For more information, see both the Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
Checklist and figure (Additional file 1 and Table 2), with
more detailed information on the execution of the trial, and
scientific, ethical and administrative elements.
Discussion
This randomised controlled trial addresses the therapeutic
potential of a herbal extract in ADHD by investigating its
efficacy, mechanism of action and value as compared to
standard treatment and placebo. Results can be partly
compared to a previously conducted study [22, 28, 29]. A
double-blind design was chosen to avoid bias, due to the
subjectivity of questionnaire responses. Behavioural as-
sessment by teachers is preferred as primary objective due
to the higher sensitivity of teachers’ ratings [58, 59]. A 10-
week treatment is considered long enough to see clear ef-
fects of both Pycnogenol® and Medikinet® Retard, though
still minimising the patient burden and thus maximising
compliance [22]. The parallel design was, therefore, also
chosen to reduce patient burden.
Pycnogenol® is a patented, proprietary powder extract
made exclusively from French maritime pine bark by Hor-
phag Research (Geneva, Switzerland). The extract is stan-
dardised to contain 70 ± 5% procyanidins. Pharmacological
studies employing in vitro, animal and/or human models
have found potent antioxidant activity, anti-inflammatory
actions, improvement of endothelial function, etc. [60]. Pyc-
nogenol® was selected for the present study based on previ-
ous research suggesting its therapeutic benefits in ADHD,
though this trial had several limitations [22, 27–29]. Further
research is needed to investigate its efficacy, mechanism of
action and value, especially compared to MPH treatment.
For example, dietary polyphenols and their metabolites
exert prebiotic-like effects, stimulating the growth of intes-
tinal microbiota, which play a fundamental role in immun-
ity [48, 61, 62]. Also the Pycnogenol® dosage is based upon
this previous clinical trial, using 1 mg/kg body weight [22].
In the present trial, due to practical reasons, 0.67–1.33 mg/
kg body weight will be applied.
Despite being the first choice medication for ADHD,
MPH is associated with various adverse effects (including
serious adverse events), some of them frequently occurring,
including irritability, insomnia, loss of appetite and head-
ache [8]. Based on data from 70 human clinical studies on
5723 healthy subjects and patients, the overall frequency of
adverse side effects due to Pycnogenol® is very low (1.8%)
and unrelated to dose or duration of use. The majority of
adverse effects observed are mild. Gastrointestinal discom-
fort, the most frequently occurring adverse effect, may be
avoided by taking Pycnogenol® with or after meals. In
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children with ADHD, 2 of 41 Pycnogenol®-supplemented
participants experienced side effects (rise of slowness and
moderate gastric discomfort). Pycnogenol® did not cause
any significant changes in blood pressure or heart rate in
four clinical studies (total n = 185). There have been no re-
ports of serious adverse effects since its introduction into
the European market around 1970 [49]. Safety trials have
demonstrated the absence of mutagenic and teratogenic ef-
fects, no perinatal toxicity and no negative effects on fertil-
ity [63]. Therefore, the use of Pycnogenol® in children is
considered to be safe.
The ADHD-RS is validated and internationally ac-
cepted, and consists of nine inattention and nine impul-
sivity and hyperactivity items based on the Diagnostic
and Statistical Manual of Mental Disorders (DSM), each
marked out on a four-point rating scale [23]. The
ADHD-RS allows comparison of results to those of pre-
viously performed trials [22, 54].
In addition to the ADHD-RS, the SEQ is used in this
trial. Though this increases the number of questions on
behaviour significantly (72 questions), the SEQ is a be-
haviour evaluation list to assess core symptoms of
social-emotional problems, including frequently occur-
ring psychiatric comorbidities of ADHD. Besides ADHD,
three other clusters of social-emotional problems are in-
corporated in the SEQ (social behaviour problems, anx-
iety and autism), with items covering the core symptoms
of these clusters according to DSM. The SEQ can be
used for screening, diagnosis and treatment evaluation.
Items are rated on a five-point scale [33].
The approved PCQ consists of 36 questions, of which 18
items are relevant with respect to specific physical and sleep
complaints, including eight domains: (1) pain (e.g. head-
ache), (2) unusual thirst or perspiration, (3) eczema, (4)
asthma or rhinitis, (5) skin problems (e.g. blotches in the
face), (6) tiredness, (7) gastrointestinal problems and (8)
sleep problems. Items, including various potential adverse
effects, are rated on a five-point scale at baseline and after 5
and 10 weeks [34]. In addition, parents will be asked
whether the participant experienced any illness during the
trial, what illness, whether any medication was taken, and
the type, dose and duration of medication intake.
The FFQ consists of 50 questions on different food
groups to be rated on a nine-point scale by parents at the
start and end of the intervention, to assess baseline dietary
habits and potential adaptations during the study, as well as
to relate potential differential effects of Pycnogenol® to diet-
ary polyphenol intake [52, 53]. Insight in global dietary
habits (e.g. whether or not the participant consumes fresh
fruit on a daily basis) is, therefore, aimed for.
Patients and especially their parents are often worried
about side effects of MPH, the standard medication for
ADHD. It is, therefore, important to take into account
side effects of Pycnogenol® and effects on comorbid
complaints. In addition, the behavioural effects of Pycno-
genol® compared to placebo, but also compared to MPH,
will be investigated. This active control is rather unseen in
research on nutritional supplements, but of great import-
ance. In one previous trial, the effect of Pycnogenol® was
compared to MPH and placebo. However, neither MPH
nor Pycnogenol® outperformed placebo, possibly due to
the short treatment period of 3 weeks [27].
Most research on nutritional supplements or medication
in ADHD predominantly assesses effects on ADHD behav-
iour. This trial, however, takes into account comorbid be-
havioural and physical symptoms, such as ODD, anxiety
and side effects, as well as a broad range of innovative im-
mune, oxidative and neurochemical biomarkers. The
analysis of gene expression and biomarkers can indicate
genetic effects and biological processes involved in the
mechanism of action of Pycnogenol® and possibly affecting
ADHD symptom expression. Research on microbiota in
ADHD in itself is novel, too. Results of this project will,
therefore, increase insight in ADHD aetiology and (dietary)
treatment options, which is highly desired by medical staff,
parents and patients.
Trial status
Not yet recruiting as of February 2016.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents*. (DOCX 100 kb)
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